Results 141 to 150 of about 143,882 (299)

Data mining for prothrombin time and international normalized ratio reference intervals in children. [PDF]

PLoS One, 2022
Shaikh MS, Ahmed S.
europepmc   +1 more source

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Yasutoshi Fujii, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Shinsuke Uchikawa, Nami Mori, Keiji Tsuji, Yosuke Suehiro, Keiichi Masaki, Michihiro Nonaka, Kenji Yamaoka, Yoshio Katamura, C. Nelson Hayes, Masataka Tsuge, Shiro Oka   +21 more
wiley   +1 more source

A super-geriatric patient with gastrostomy underwent life-threatening prothrombin time-international normalized ratio prolongation by warfarin following fasting and antibiotic therapy. [PDF]

Clin Case Rep, 2023
Saeki M, Watanabe A, Momo K, Kashiwabara Y, Iha T, Nagata T, Fujiwara A, Tanaka K.   +7 more
europepmc   +1 more source

Citrate anticoagulation for extracorporeal circuits: Effects on whole blood coagulation activation and clot formation [PDF]

, 2001
Calatzis, A., Schiffl, Helmut, Schramm, W., Spannagl, M., Toepfer, Marcel   +4 more
core   +1 more source

Use of andexanet alfa: A British Society for Haematology position statement

British Journal of Haematology, EarlyView.
Richard J. Buka, Deepa J. Arachchillage, Catherine N. Bagot, Gary Benson, Charlotte A. Bradbury, Nicola Curry, Beverley J. Hunt, David J. Sutton, Mari R. Thomas, John Paul Westwood, Karen Breen   +10 more
wiley   +1 more source

Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients With Cirrhosis and Hepatic Edema: A Nationwide Multicenter Cohort Study

Hepatology Research, EarlyView.
In a nationwide multicenter cohort, an early response to tolvaptan (≥ 1.5‐kg weight loss within 7 days) was independently associated with improved long‐term survival in patients with cirrhosis and hepatic edema. Early initiation before renal impairment or hyponatremia may optimize treatment response and prognosis. ABSTRACT Aim Hepatic edema indicates a
Kaori Koyano, Taeang Arai, Hidenori Toyoda, Keizo Kato, Joji Tani, Suguru Ogura, Tomomi Okubo, Korenobu Hayama, Norio Itokawa, Toshifumi Tada, Akito Nozaki, Atsushi Hiraoka, Kentaro Matsuura, Toru Ishikawa, Naoto Kawabe, Tsunamasa Watanabe, Koichi Takaguchi, Asahiro Morishita, Hironao Okubo, Motoh Iwasa, Hiroki Nishikawa, Yasuhito Tanaka, Masanori Atsukawa   +22 more
wiley   +1 more source

Mild Prolongation of Prothrombin Time Does Not Affect the Safety and Prognosis of Transjugular Intrahepatic Portal Shunt: Based on Real-World Data. [PDF]

Turk J Gastroenterol, 2023
Bai Y, Liu J, Chen Y, Yang C, Wang Y, Wang C, Ju S, Zhou C, Huang S, Li T, Yao W, Yao J, Xiong B.   +12 more
europepmc   +1 more source

Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI

Hepatology Research, EarlyView.
Hepatocellular carcinoma (HCC) is a common type of liver cancer. Recently, combination therapy with atezolizumab plus bevacizumab has become a standard systemic treatment for patients with unresectable HCC. Some HCCs show high signal intensity on the hepatobiliary phase of Gd‐EOB‐DTPA–enhanced MRI.
Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masakatsu Tsurusaki, Keitaro Sofue, Yoshihiko Yano, Hidenori Toyoda, Atsushi Hiraoka, Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki, Norio Itokawa, Masanori Atsukawa, Kazuhito Kawata, Kazuto Tajiri, Joji Tani, Toru Ishikawa, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Takashi Kumada, Naoshi Nishida, Yuzo Kodama   +24 more
wiley   +1 more source

Anemia-Associated Platelets and Plasma Prothrombin Time Increase in Patients with Adenomyosis. [PDF]

J Clin Med, 2022
Lin Q, Li T, Ding S, Yu Q, Zhang X.
europepmc   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source